oncotarget 2018

Oncotarget (a primarily oncology-focused, peer-reviewed, open access, weekly journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical

Oncotarget (a primarily oncology-focused, peer-reviewed, open access, weekly journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical

Besides, 84% scientific research articles published by Oncotarget have received at least 1 citation in 2018. In addition to the 2-year Impact Factor, the 3-year Impact Factor and 5-year Impact Factor can provide further insights into the impact of Oncotarget.

2018 年,Oncotarget 期刊將不再被 SCI 資料庫收錄。丁香園與科睿唯安官方確認並核實了這一訊息。科睿唯安(Clarivate Analytics),前身為湯森路透智慧財產權與科技事業部,旗下 Web of Science 平臺包含科學引文索引,即我們常說的 SCI。

Oncotarget. 2018; 9(19): 14764-14790. Impact Journals, LLC, www.impactjournals.com, meets the Wellcome Trust Publisher Requirements, and is now a member of the Wellcome Trust List of Compliant Publishers Interviews with outstanding authors Editors-in

Oncotarget. 2018; 9(19): 14764-14790. Impact Journals, LLC, www.impactjournals.com, meets the Wellcome Trust Publisher Requirements, and is now a member of the Wellcome Trust List of Compliant Publishers Interviews with outstanding authors Editors-in

Oncotarget is a twice weekly peer-reviewed open access bio-medical journal covering research on all aspects of oncology and publishing sub-sections on topics beyond oncology. The journal was established in 2010 and is published by Impact Journals. The editors-in-chief are Mikhail Blagosklonny and Andrei V. Gudkov. In 2017, the journal

Edited by: Mikhail Blagosklonny, Andrei V. Gudkov

Oncotarget 期刊 繼2017年10月被MEDLINE資料庫除名後, 2018年1月也被 Journal Citation Reports (JCR) 除名 (dropped), 可預見該期刊未來將不會再有Impact Factor。 有關期刊變動資訊,請參考科睿唯安 (Clarivate Analytics) 「Master Journal List」。

Oncotarget (a primarily oncology-focused, peer-reviewed, open access, weekly journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical

Cited by: 7

I really enjoyed oncortarget weekly journals, it gives full insight on oncology, aging, immunology a nd various medical terms. Especially the thorough research on cancer, it is well detailed and properly researched. Well informative and the push to find treatments for

4.4/5(15)

Inositol 1,4,5-trisphosphate receptor, type 2 (ITPR2) is a key regulator for the activity of calcium ion transmembrane transportation, which plays a critical role in cell cycle and proliferation. However, the clinical impact of ITPR2 in cytogenetically normal acute myeloid

Oncotarget, a weekly journal, is indexed/archived on?PubMed?and?PMC. oncotarget给我发email说:News:?(June 2019), Scopus has released its latest 2018?ratings. Oncotarget is in?Q1?(highest rank) again.? Furthermore, Oncotarget ranks No. 1 for total

「從2018年開始,我們將不再收錄《oncotarget》這個雜誌」。科睿唯安中國官方工作人員告訴上游新聞記者,「對於2017年12月《oncotarget》雜誌的文章,我們還沒有得到最終是否會收錄的消息。現在還在等最後的評估和溝通的結果,無法保證12月的會不會

Impact Factor of Oncotarget, 1949-2553, Journal Impact Factor report TOP PUBLISHERS Elsevier Springer-Verlag Taylor & Francis John Wiley and Sons Sage Publications SciELO

Starting from January 2018, Oncotarget is no longer listed in SCIE (Science Citation Index Expanded). This is shocking news to a lot of scientists because the journal was deemed a “rising star” in the field of molecular biology & genetics just a short three months

Oncotarget Impact Factor, IF, number of article, detailed information and journal factor. ISSN: 1949-2553. Journal Impact Enter journal title, issn or abbr in this box to search

一月 11, 2018 新闻 昨天,一则《oncotarget》被SCI踢出的消息不胫而走,让已经投稿该刊的中国医学科研人员及即将毕业的学生着实惊慌起来,但从消息源来看,仅是科睿唯安的工作人员与读者的邮件内容上说到,该工作人员在邮件内容上回复:“关于期刊

10/1/2018 · 官网主页预测:2018年Oncotarget影响因子将会是5.5至5.6分左右。 目前的即时影响因子是3.97分,高于去年同期水平0.32分。 的确经常听到一些人不断黑这个杂志,不可否认由于它收文数量巨大,的确有灌水的可能,但是平心而论,还是有很大一部分

Oncotarget (a primarily oncology-focused, peer-reviewed, open access, weekly journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical

近日,深受国内学者欢迎的医学神刊Oncotarget被爆出已由SCI数据库剔除,从2018年起不再被SCI收录,最终结果有待科睿唯安工作人员进一步证实。Oncotarget从2017年9月起已不再被MEDLINE数据库检索,前景堪忧。目前国内部分单位及课题组已将其列入黑名单

Articles from Oncotarget are provided here courtesy of Impact Journals, LLC

位置: 8600 Rockville Pike, Bethesda, MD

The latest Tweets from Oncotarget (@OncotargetJrnl). An online multidisciplinary journal, #Oncotarget provides members of the scientific community with access to research within oncology. #medical #scholarly. Orchard Park, NY

《oncotarget》被SCI剔除 新聞: http://www.kaixian.tv/gd/2018/0111/64816.html 上oncotarget官網目前沒有看到消息 想請問各位版大這則新聞是

Oncotarget – 影响因子 Oncotarget的2018年影响因子 为 3.710 (2019年最新数据)。 与历年影响因子数据相比,Oncotarget 2018年影响因子下降了 22.55 % 。 2018-19年Oncotarget的最新影响因子分区 为 1区。 影响因子现已成为国际上通用的期刊评价指标,它不仅是一

2018-01-09 有影响因子的一定是SCI吗 2017-09-05 oncotarget 什么时候算是正式出版 2017-06-18 文章刚刚被Oncotarget杂志接收,但接下来该怎么办 2016-09-12 oncotarget多久能在sci搜索到 2016-07-22 oncotarget在哪个数据库 2016-10-09 oncotarget大修 容易接收

狀態: 發問中

小弟之前認真地審了幾篇投稿到Oncotarget的論文, 作者通常都是對岸的教授,醫學領域。 但感覺很奇怪的是,這本期刊 (New impact factor (IF2016) is up to 5.168) 從來沒有回覆我editor decision/ other reviewer’s comments。

最近似乎就oncotarget是否要被SCI踢出来这事情,真真假假的报道挺多。以我的观点来看,它被踢是正常的;它不被踢也迟早要被踢!就像当年它的影响因子还在7点多的时候,我就预言oncotarget药丸一样,结果就直接掉到5点多,然后关于神刊的报道就开始多

确实,有的文章也就是2-3分水平 胖子武工队 2018-08-02 00:00:00 发表: 诺奖得主,就是个牌位,广告效应,一年几千篇,文章质量良莠不齐,很多质量根本达不到五分,水文很多,什么利益纠纷,都是洗白自

近日,學術期刊界炸響了一聲驚雷:Oncotarget雜誌將於2018年不再被SCIE收錄。自科研江湖中存在四大灌水神刊後,不知有多少phds被解救於水火之中,而這其中影響因子穩定在5分左右的Oncotarget雜誌就牢牢地霸占了一席,成為眾多學者

1月10日,科睿唯安中國官方向上游新聞記者(全國爆料熱線:[email protected])證實:SCI從2018年開始剔除《oncotarget》雜誌,「這種剔除是正常的,我們的收錄是一個動態的過程,只要不符合我們的質量要求,我們每天都有可能剔除」。

近日,學術期刊界炸響了一聲驚雷:Oncotarget雜誌將於2018年不再被SCIE收錄。自科研江湖中存在四大灌水神刊後,不知有多少phds被解救於水火之中,而這其中影響因子穩定在5分左右的Oncotarget雜誌就牢牢地霸占了一席,成為眾多學者

1月10日,科睿唯安中國官方向上游新聞記者(全國爆料熱線:[email protected])證實:SCI從2018年開始剔除《oncotarget》雜誌,「這種剔除是正常的,我們的收錄是一個動態的過程,只要不符合我們的質量要求,我們每天都有可能剔除」。

其中,Oncotarget和Aging榜上有名。当然,这并不是说上榜了就是实锤的水刊,而是提醒科学家在发paper的时候要足够小心,避免被人坑。毕竟,这个榜单并不是无中生有。20180113补充1(原答案在后面): 有些小伙伴不禁要问,为何在收稿量增大且稿件质量

6月20日,Clarivate Analytics 发布2019年的期刊引证报告(基于2018年的数据),收录了来自五大洲81个国家的12538类期刊,涵盖236个学科。小萨第一时间为您整理顶尖期刊影响因子,先睹为快。 相比于2018年前三甲都是

We just confirm the news about Oncotarget is no longer indexed in MEDLINE, however articles published in Oncotarget can still be searched and found in PubMed, one of the most frequently used search engine for references and abstracts on life sciences and

2018/2019-3.046 869 7177 2017-2.656 585 5065 2016-1.653 785 1908 2015-2.272 414 1260 2014-2.311 241 737 2013-1.342 200 222 2012-2.073 54 115 2011-1.261 19 63 2010-0.176 22 6 You may also be interested in the following journals Oncotarget

2018 3.707 Total Cites Self-Cites Evolution of the total number of citations and journal’s self-citations received by a journal’s published documents during the three previous years. Journal Self-citation is defined as the number of citation from a journal citing

OncoTargets and Therapy is an international, peer-reviewed journal focusing on the molecular diagnosis of and targeted molecular or precision therapy for all types of cancer. This journal explores the evidence behind new and existing therapies to aid their informed

· Oncotarget:血清外泌体miR-665可能是一种新的肝癌微创诊断和预后生物标志物 · Oncotarget:外泌体miR-141-3p可调节成骨细胞活性来促进前列腺癌的进展 · Oncotarget:循环miRNA可用于卵巢癌的早期精准筛查 · Oncotarget:不同外泌体在草酸盐肾结石形成

Oncotarget 雖然文章放量(3204 –> 6625),但或許受惠於整體癌症領域研究的成長,impact factor 竟仍逆勢上漲,實在厲害。 雖然仍在 ONCOLOGY 類的 Q1,但排名的確是下滑了,從 36/213 掉到 44/217,百分位數也從 83.333 掉到 79.954。 這本期刊的經營